Palliative Care for Children with Central Nervous System Malignancies

Peter H. Baenziger MD, Peyton Manning Children’s Hospital at St. Vincent Indianapolis
2001 West 86th Street, Indianapolis, IN 46260

Karen Moody MD, University of Texas, MD Anderson Cancer Center
1515 Holcomb Blvd., Unit 87, Houston Texas 77030
Kmoody@mdanderson.org (corresponding author)

Abstract

Children with central nervous system (CNS) malignancies often suffer from high symptom burden and risk of death. Pediatric palliative care is a medical specialty, provided by an interdisciplinary team, which focuses on enhancing quality of life and minimizing suffering for children with life-threatening or life-limiting disease, and their families. Primary palliative care skills which include basic symptom management, facilitation of goals-of-care discussions, and transition to hospice can and should be developed by all providers of neuro-oncology care. This chapter will review the fundamentals of providing primary palliative care

Keywords: palliative care, child, brain, neoplasm, neuropathic pain, pain, symptoms, hospice
Introduction

Palliative care for children is critical to providing excellent care for some of the most vulnerable patients. Providers caring for children with life-threatening illness should have a fundamental understanding of how to assist patients and families in establishing goals-of-care and essential pain and symptom management skills, the mainstays of the field of hospice and palliative medicine. The American Academy of Pediatrics outlines principles to guide palliative care practice including: 1) providers have an obligation to ensure interventions are only used when potential benefits outweigh risks; 2) the goal of palliative care is to enhance quality of life despite disease trajectory; 3) palliative care focuses on symptoms and conditions; and 4) palliative care teams work towards healthy bereavement for the family of the patient. A multidisciplinary approach to supporting families, including a social worker, psychologist, and child life therapist most fully encompasses the wide variety of burdens faced by patients suffering neurologic tumors. Most consider the standard for an excellent team to be inclusive of a physician, nurse, social worker, spiritual advisor, and a child life therapist.

While the most common forms of cancer in children (i.e. leukemia) now boast very high cure rates, the overall mortality rate in pediatric solid neurologic tumors is greater than 25%. Regardless of “high-risk” or “low-risk”, patients with solid neurological tumors suffer the adverse effects of chemotherapy, radiation, surgery, and direct disease sequelae which may be ameliorated with palliative care.

Facilitating Discussion and Decisions

A critical aspect of primary palliative care is to assist with establishing goals-of-care with patients and families. This is done across a series of conversations and begins with an assessment of the patient’s and family’s understanding of their illness, treatments, and prognosis. The medical decisions faced by parents and providers on behalf of children with brain tumors are numerous, frequent, high-stakes, and should align with goals of care. Establishing goals requires some determination of the patient’s and family’s values and priorities. This information helps develop the framework for establishing goals-of-care and includes weighing benefits and burdens of treatment and factoring in individual priorities and values. A key to facilitating these difficult conversations is to communicate in a way that “meets people where they are”--essentially by not giving too much or too little information (which can be assessed through inquiry) and by enabling the patient’s and family’s values to drive the conversation. It is best accomplished when there is a consideration the broader view of a patient and family, beyond the disease context, to include their personal lives, their community, their social, emotional, and spiritual wellness.

Communicating well is important to patients, decreases uncertainty, and may improve hope and result in a decline in decision regret. Most parents would prefer to receive information about palliative care treatment options for their children than for this information to be withheld. Young adults with cancer who have experienced an honest prognostic discussion
with their providers demonstrate increased trust in providers, increased peace and hope, and
decreased distress. See Table 1 for communication tools.

Table 1. Palliative Care Communication Tools

<table>
<thead>
<tr>
<th>Delivering Bad News</th>
<th>Verbal Responses to Emotion</th>
<th>Non-verbal Response to Emotion</th>
</tr>
</thead>
<tbody>
<tr>
<td>“SPIKES”: Setting: Prepare the setting for the conversation and minimize distractions.</td>
<td>“NURSES”: Naming the emotion statement: “I hear frustration in your voice.”</td>
<td>“SOLAR”: Squarely face the patient.</td>
</tr>
<tr>
<td>- Perception: Assess the caregiver’s perception of the clinical information.</td>
<td>-Understanding statement: “I understand this is upsetting news.”</td>
<td>-Open body posture.</td>
</tr>
<tr>
<td>-Invitation: Ask permission to deliver new information.</td>
<td>-Respect statement: “I can see how dedicated you have been to your son’s care over these three months.”</td>
<td>-Lean towards the patient.</td>
</tr>
<tr>
<td>-Knowledge: Provide the main message up front, simply.</td>
<td>-Support statement: “We are here to help you and your family.”</td>
<td>-Eye contact.</td>
</tr>
<tr>
<td>-Emotion: Respond empathically to emotion.</td>
<td>-Explore statement: “Tell me about what you were hoping to hear today.”</td>
<td>-Relaxed body posture.</td>
</tr>
<tr>
<td>-Strategy / Summary: Summarize the encounter and what will happen next.</td>
<td>-Silence: Providing silence in the room can passively, yet explicitly recognize emotions.</td>
<td></td>
</tr>
</tbody>
</table>

Palliative care principles obligate providers and families to provide a developmentally appropriate explanation of disease and the burdens expected to the patient within the context of values, culture and preferences. Earlier discussion of prognosis may be beneficial to allow for processing of information and allowing for earlier integration of prognosis into decision making. Intentional, compassionate discussions of death should include consideration of the child’s developmental maturity, understanding of death, prior experiences with death, and the cultural and religious milieu in which the child lives, including family preference about if, when, and how information is disclosed to the patient. Families should be encouraged to discuss the child’s fears, meeting them at a developmentally appropriate level. It is important to note that studies demonstrate children are often aware of their grave prognosis before parents or care teams engage in a formal conversation and that children may avoid the topic to protect their parents.

A common decision put to families is whether and when to enroll in hospice. Hospice is a comprehensive home care program, with 24-hour, on-call nurse visits, home medication delivery, continuous 1:1 nursing if needed, and bereavement support. Eligibility for hospice
only requires a reasonable possibility of death within 6 months; a do not resuscitation order is not required. Hospice utilizes a multidisciplinary approach focusing on comfort and quality of life. Advance care planning is important for end-of-life care, including the patient’s / family’s preference for location of death. Unique to pediatrics is the concept of “concurrent care” which allows children to “concurrently” receive both curative therapies and hospice. Another decision many families face is phase one trial enrollment which may provide families with a sense of hope, legacy, and dignity. The burdens of the trial should be balanced with the family’s sense of benefit. Enrolling in clinical trials does negative affect engagement with palliative care teams.

**Symptom Burden**

The symptoms experienced by children with brain tumors are varied and can be quite burdensome. The location of the tumor may predict likely burdens: supratentorial tumors are associated with seizures, coma, and nausea and vomiting; infratentorial tumors are associated with ataxia; brain stem tumors are associated with speech disturbances, cranial nerve paralysis (swallowing dysfunction), and tetraparesis. In addition to the most common symptoms of other childhood cancers (fatigue, pain, dyspnea), children with brain tumors can also suffer dysphagia and dysarthria, hearing and vision loss, paralysis, seizures, agitation, headache, and cognitive and behavioral changes.

**Oromotor Dysfunction and Secretions**

Expert experience provides the bulk of treatment recommendations for oromotor dysfunction, which include speech therapy evaluation, thickening of feeds, and treatment with steroids to acutely reduce edema. Upon presentation of dysphagia, a discussion about continuing oral feeds including the risks (such as aspiration pneumonia) and benefits (child’s enjoyment of favorite foods, tastes, experiences; social interactions surrounding meals) is crucial.

Secretions often become difficult for patients to manage as they lose their oral motor proficiency and their alert mental status. The goal of treatment is to decrease respiratory distress, aesthetic distress of secretions, and to attain maximum patient comfort. Medicines used are muscarinic anticholinergics like glycopyrrolate, scopolamine, or atropine. Glycopyrrolate does not cross the blood brain barrier and thus spares patients from central nervous system side effects. Scopolamine patches pose a convenient transdermal delivery system and are approved for patients greater than 45kg. Atropine ophthalmic 1% solution can be given sublingually; 1 drop every 4 hours providing 0.27 mg atropine per dose. Other treatment strategies are regular oral care and suction, lateral positioning the patient, and music to dampen the noise. Families can be reassured that the rattling noise is not painful (an analogy to snoring works well) and deep suction will generally cause more harm than benefit.

**Communication Difficulties**

Children with neurologic tumors may suffer frustrating decreases in their ability to communicate due to dysarthria, aphasia, or hearing deficits. Assisted communication
devices require significant time to learn thus are less useful than simple tools like dry erase boards or symbol books.\textsuperscript{35,36,37} Speech, occupational, and physical therapies can have a significant impact by slowing the decline of key functional quality of life skills such as speech and swallowing.\textsuperscript{38,39}

**Nutrition and Hydration**

As oromotor dysfunction progresses, nutrition and hydration often become concerns that need particular attention. The fundamental nature of care through feeding and hydration makes discussions particularly challenging. Foregoing nutrition and or hydration should be framed by prognosis and focused on the experience of the patient. For those patients who can no longer feed by mouth yet express hunger or other symptoms due to lack of intake, the benefits to intervening may outweigh the risks. Generally, if a child is likely to live longer than 90 days, it is reasonable to use more invasive solutions (surgically placed feeding tube, total parenteral nutrition) if such procedures are aligned with family and patient values. If the prognosis is shorter, a nasogastric or nasojejunal feeding tube is more appropriate, with decreased risks, and foregoing feeds and fluids altogether is also an acceptable option for some. The burdens of feeds should not be forgotten; patients may feel discomfort from the feed itself, the tubes, or may have adverse responses to their change in appearance. When the primary goal is patient comfort, even when oral feeding poses an aspiration risk, it is reasonable to allow small amounts of intake for enjoyment. Finally, offering hydration without nutrition or in the setting of impending death, often leads to increased symptom burden (dyspnea, swelling, pain) compared to mild dehydration.\textsuperscript{40}

**Headache**

Headache occurs in around 36\% of patients with brain tumors.\textsuperscript{41} The primary treatment modality is pharmacologic, including acetaminophen, opioids, and dexamethasone. Medications that address neuropathic pain can be beneficial but often take a week or more to be effective. Low dose methadone (0.04 mg/kg/dose BID), is an opioid that also has NMDA receptor antagonist properties and can be particularly efficacious in cancer related headache but may necessitate consultation with a palliative care or pain specialist comfortable with dosing and monitoring.\textsuperscript{42} Methadone can be compounded into a 10 mg per mL solution for easy sublingual administration near end of life. Morphine can be similarly compounded into highly concentrated sublingual solutions. When using steroids for headache, the lowest possible effective dose should be used, and weaning should be considered after control of symptoms. NSAIDs (non-steroidal anti-inflammatory drugs) are typically avoided due to risk of bleeding at the tumor site and due to the risk of gastric ulcers with concurrent use of steroids.

**Seizures**

Seizures occur in 30-50\% of patients with brain tumors. Seizures cause distress to the patient and family and may also cause worsening cognitive and behavioral functioning.\textsuperscript{43,44} The treatment goals are to control seizures and to optimize periods of alertness. There is no evidence to support routine prophylactic antiepileptic use in the absence of a documented
seizure history and these agents may cause sedation or agitation. For acute seizure treatment, the benzodiazepines are most helpful. Diazepam and lorazepam can be given rectally, and lorazepam and midazolam are both absorbed intranasally.

For chronic seizure suppression, levetiracetam as a broad acting staple, has few adverse effects, is well tolerated, and is often effective. Many patients experience a brief, initial period of aggression on levetiracetam; if it does not resolve within several weeks, vitamin B6 supplementation has been shown in a small study to reduce the behavior change. Pediatric neurology consultation is prudent for refractory seizures, status epilepticus, or patient intolerance due to adverse effects.

Because neurologic tumors are associated with dysphagia concentrated sublingual compounds and rectally administrated antiepileptic medications often becomes important. Pharmacists are an important resource in this regard. Diazepam is the primary rectal choice as it comes in a suppository and acts more quickly than other antiepileptics given by this route.

### Nausea and Vomiting

Nausea and vomiting in the setting of pediatric neural tumors may be due to treatment or direct effects of the tumor. The vomit center receives input from two central nervous system controlling areas (chemoreceptor trigger zone; nucleus tractus solitarius) and one peripheral input source (vagus nerve) which use a multitude of neurotransmitters (histamine, acetylcholine, dopamine, serotonin, neurokinin). Treatment goals are to reduce nausea and vomiting to the point that patients can interact with family, can take by mouth foods they enjoy, and maintain nutrition and hydration.

Consider whether nausea is due to direct pressure from tumor, chemotherapy, toxins (uremia, hepatic failure, hypercalcemia), vestibular pathology, or gastrointestinal pathology (obstruction, ulcers, mucositis, constipation). When the cause is increased intracranial pressure, steroids are first-line treatment. When chemotherapy or radiation induced nausea and vomiting is expected, prophylaxis is recommended, and several published guidelines for children exist. For best control of nausea and vomiting, one should utilize both a scheduled medication as well as an as-needed medication; choosing medications from different classes is also ideal. See Table 2 for a list of antiemetics and dosages. Non-medical therapies can include hypnosis and acupuncture. Additionally, practical remedies such as treating constipation, removing noxious smells, opioid rotation, emotional support, and modifying meals to be smaller and more frequent.

### Table 2. Antiemetics

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Dose</th>
<th>Forms</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NK-1 Antagonist</td>
<td>Aprepitant (Emend)</td>
<td>Day 1: 3 mg/kg PO (max 125 mg) Day 2, 3: 2 mg/kg PO (max 80 mg)</td>
<td>Capsule, suspension</td>
<td>Approved for chemotherapy induced nausea/vomiting (CINV). Assess for</td>
</tr>
<tr>
<td></td>
<td>Drug Name</td>
<td>Dose/Directions</td>
<td>Formulations</td>
<td>Notes</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Steroid</strong></td>
<td>Dexamethasone (Decadron)</td>
<td>10 mg/m² IV/PO daily (reduce to 5 mg/m² if using with aprepitant)</td>
<td>IV, tablet, solution</td>
<td>This is the CINV dose; alternate dosing is used for brain edema</td>
</tr>
<tr>
<td><strong>5HT3 Antagonist</strong></td>
<td>Ondansetron (Zofran)</td>
<td>0.15 mg/kg/dose IV/PO q8h (max 8 mg/dose)</td>
<td>IV, tablet, oral disintegrating tablet, solution</td>
<td>5HT3 antagonists have equivalent efficacy at comparable doses</td>
</tr>
<tr>
<td></td>
<td>Granisetron (Kytril)</td>
<td>0.04 mg/kg IV daily or PO q12h (max 1 mg/dose) age &gt;12 years: 1-2 mg PO/IV q12 hours</td>
<td>IV, tablet, solution (custom compounded), patch (available as outpatient prescription for adolescents)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Palonosetron (Aloxi)</td>
<td>0.02 mg/kg IV once prior to chemo. If necessary, may re-dose 72 hours later</td>
<td>IV</td>
<td></td>
</tr>
<tr>
<td><strong>Phenothiazine</strong></td>
<td>Promethazine (Phenergan)</td>
<td>0.25 mg/kg PO/IV q6h (max 25 mg/dose)</td>
<td>IV, tablet, syrup, suppository, topical gel</td>
<td>Contraindicated in children &lt; 2 years old. Anticholinergic.</td>
</tr>
<tr>
<td></td>
<td>Prochlorperazine (Compazine)</td>
<td>0.1 mg/kg/dose IV/PO q6h (max 10 mg/dose)</td>
<td>IV, tablet, suppository</td>
<td>Contraindicated in children &lt; 2 years old or &lt; 9 kg; anticholinergic and anti-dopaminergic; risk of extrapyramidal symptoms</td>
</tr>
<tr>
<td><strong>Prokinetic</strong></td>
<td>Metoclopramide (Reglan)</td>
<td>0.1-0.5 mg/kg IV/PO q6h (max 10mg) Adolescents: 5-10mg IV/PO q6h</td>
<td>IV, tablet, suspension</td>
<td>Risk of tardive dyskinesia, especially with prolonged use; may use with oral diphenhydramine. Anti-dopaminergic</td>
</tr>
<tr>
<td>Drug Class</td>
<td>Drug Name</td>
<td>Dosage Information</td>
<td>Formulation</td>
<td>Risk of Sedation, Respiratory Depression, Coma, and Death When Used with Opioids</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Benzodiazepine</td>
<td>Lorazepam (Ativan)</td>
<td>0.04 mg/kg IV/PO q8h (max 2 mg/dose)</td>
<td>IV, tablet, suspension</td>
<td></td>
</tr>
<tr>
<td>Atypical Antipsychotic</td>
<td>Olanzapine (Zyprexa)</td>
<td>0.14 mg/kg/dose PO qHS (max 5-10 mg/dose)</td>
<td>tablet, orally disintegrating tablet</td>
<td>Antidopaminergic, anticholinergic, and 5HT2 antagonist.</td>
</tr>
<tr>
<td>Cannabinoid</td>
<td>Dronabinol (Marinol)</td>
<td>5 mg/m2 PO BID-QID (max 5-10 mg/dose)</td>
<td>Capsule</td>
<td>Contraindicated with sesame oil hypersensitivity</td>
</tr>
<tr>
<td>Antihistamine</td>
<td>Diphenhydramine</td>
<td>0.5 mg/kg PO q6h</td>
<td>Oral, elixir</td>
<td>Avoid IV use due to dependency and sedation risk. Also, may use to manage EPS side effects.</td>
</tr>
<tr>
<td>Anticholinergic</td>
<td>Scopolamine (Transderm Scop)</td>
<td>1.5 mg patch changed q72 hours</td>
<td>Patch</td>
<td>For use in patients &gt; 45 kg</td>
</tr>
<tr>
<td>Butyrophenone</td>
<td>Haloperidol (Haldol)</td>
<td>3-12 y/o: start 0.05mg/kg/day divided bid-tid &gt; 12 start 0.5 mg per dose bid-tid, up to 4 mg /dose q 6 hours</td>
<td>PO tabs/IV/SC</td>
<td>Anti-dopaminergic. Risk of severe extrapyramidal symptoms, prolonged QT and granulocytopenia</td>
</tr>
</tbody>
</table>

**Pain**

Pain is reported by many children and adolescents with brain tumors, and may be due to the cancer itself, the treatments received, and the procedures performed. Most patients with neurological tumors benefit from pain medicines at some point in their disease process (84%). Neuropathic pain caused by the tumor can be particularly challenging to treat and may require polypharmacy for best results.

Other manifestations of “total pain” are addressed hereafter, including psychological, social, emotional, and spiritual elements. These must be treated in parallel to physical pain as they are codependent.

Treatment of pain in the patient with neuro-oncological disease begins with the foundations of pain in other clinical care arenas: assessment, identifying type of pain, intervention, and reassessment. Validated scales should be used whenever possible to track progress. The FLACC scale is useful for caregiver observation of infants and other non-verbal patients. For 3 years and older, the Wong Baker FACES scale gives an age appropriate visual scale and, for ages 9 and older, a simple 0-10 numerical rating scale is appropriate.
The two fundamental types of pain are nociceptive and neuropathic. Nociceptive pain includes somatic (muscle and bone) or visceral (organs) pain. Somatic pain is typically localized and described as “sharp”, “aching” or “throbbing” whereas visceral nociceptive pain is poorly localized and described in a variety of ways (“gnawing”, “cramping”, “pressure”, nausea, vomiting). Neuropathic pain is typically due to damage to nerves and is described as “burning”, “needles”, “numbness”, or aggravated by touch. Much of the pain experienced in neuro-oncology patients is of mixed type as brain tumors directly press on neuronal tissue and therefore a mixed approach is commonly undertaken.

Nonpharmacologic treatments should accompany the pharmacological approach for patients with any severity of pain; these include environmental changes, treating comorbid symptoms (fear, anxiety, depression), and integrative approaches such as: hypnosis, mind-body therapies, heat and cold stimulation, massage, acupuncture, physical therapy, exercise, biofeedback, art therapy, guided imagery, and distraction.

Pharmacologically, mild nociceptive pain is treated with acetaminophen; moderate to severe nociceptive pain is treated with opioids. For those with pain at least every other day, employ a long-acting, scheduled agent as well as a short acting as-needed agent. Short acting agents should be 10-15% of the daily opioid morphine equivalent dose and given every 2-4 hours as needed. Methadone is a very useful long acting mu-agonist and NMDA antagonist agent available in a variety of forms for easy pediatric dosing. Consultation with a provider comfortable with dosing and management may be necessary. See Table 3 for nociceptive pain medications and dosages.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Route</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>Oral, IV, Rectal</td>
<td>10mg/kg IV q6 hours or 15 mg/kg po q4 hours.</td>
<td>Avoid in liver disease or consult with hepatologist /GI specialist regarding dosing.</td>
</tr>
</tbody>
</table>

### Table 3. Nociceptive agents

<table>
<thead>
<tr>
<th>Rout e</th>
<th>Dose</th>
<th>Onset (minut es)</th>
<th>Peak Effec t (hour s)</th>
<th>Durati on (hours)</th>
<th>Initial Schedul ed Dosing in Opioid</th>
<th>Available Oral Dose Formulation s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Short-Acting Dose in an Opioid Naïve Patient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Form</td>
<td>Dose Range</td>
<td>Max Dose</td>
<td>Onset</td>
<td>Duration</td>
<td>Short-acting</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
<td>--------------</td>
<td>----------</td>
<td>-------</td>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>Tramadol</td>
<td>PO</td>
<td>1-2 mg/kg/dose (max 25-50 mg)</td>
<td>30-60</td>
<td>1.5</td>
<td>3-7</td>
<td>Short-acting: every 4-6 hours</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>PO</td>
<td>0.1-0.2 mg/kg/dose (max 5-10 mg)</td>
<td>10-20</td>
<td>1-3</td>
<td>4-8</td>
<td>Short-acting: every 6 hours</td>
</tr>
<tr>
<td>Morphine</td>
<td>PO</td>
<td>0.2-0.5 mg/kg/dose (max 5-15 mg)</td>
<td>30</td>
<td>0.5-1</td>
<td>3-6</td>
<td>Short-acting: PO: every 4 hours. Long-acting: varies by product</td>
</tr>
<tr>
<td></td>
<td>IV/SC</td>
<td>0.05-1 mg/kg/dose (max 2-3 mg)</td>
<td>5-10</td>
<td>N/A</td>
<td>N/A</td>
<td>Every 4 hours</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>PO</td>
<td>0.1-0.2 mg/kg/dose (max 5-10 mg)</td>
<td>10-15</td>
<td>0.5-1</td>
<td>3-6</td>
<td>Short-acting: every 4 hours Long-acting:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>every 12 hours</td>
<td>acting: 10, 15, 20, 30, 40, 60, 80 mg tablets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-------------</td>
<td>-------------</td>
<td>---------------</td>
<td>---------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>PO</td>
<td>0.03-0.06 mg/kg/dose (max 1-3 mg)</td>
<td>15-30</td>
<td>0.5-1</td>
<td>3-5</td>
<td>Short-acting: every 4 hours</td>
</tr>
<tr>
<td></td>
<td>IV / SC</td>
<td>0.01-0.015 mg/kg/dose (max 0.5-1.5 mg)</td>
<td>15-30</td>
<td>N/A</td>
<td>4-5</td>
<td>Every 4 hours</td>
</tr>
<tr>
<td>Methadone</td>
<td>PO/SC/PO</td>
<td>0.04 mg/kg/dose BID and titrated weekly to effect</td>
<td>30 minutes (po)</td>
<td>3-5 days</td>
<td>Increases with repeat doses up to 60 hours</td>
<td>Tablet, Liquid</td>
</tr>
</tbody>
</table>

Reassessment is critical to pain control and should be performed at a frequency consistent with the medications used (consider expected time-to-onset and duration of action) and pain severity. Children suffering pain deserve aggressive pain control which may require escalating doses of opioids significantly and rapidly. There is no empiric upper limit dose on opioids; however, an individual may reach their upper limit when he/she experiences increased side effects without additional benefit to pain control. The treatments should follow the “2-step ladder” determined by the World Health Organization: Step 1 includes acetaminophen and/or NSAIDs for mild pain +/- non-opioid adjuvants; Step 2 adds opioids for more severe pain. Medication choices should be personalized for the patient, considering allergies, comorbidities, drug interactions, adverse effects, social support, and cultural perspectives.

Neuropathic pain in children is treated primarily with gabapentinoids, and/or tricyclic antidepressants, which decrease CNS excitatory neurotransmission. Again, methadone with its NMDA antagonism is also a helpful medication when pain is severe and chronic. Clonidine, topiramate, and duloxetine may also be useful, particularly when agitation, headache, or depressed mood are present, respectively. See Table 4 for neuropathic agents. Adjuvant medications to treat comorbid painful conditions such as muscle spasms, abdominal cramps, and chemotherapy induced peripheral neuropathy are shown in Table 5.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabapentin</td>
<td>Day 1: 5 mg/kg/dose (max 300 mg/dose) PO at bedtime</td>
<td>Comes in a liquid. May cause drowsiness, dizziness, and peripheral edema. Dose adjust for renal impairment.</td>
</tr>
<tr>
<td></td>
<td>Day 2: 5 mg/kg/dose (max 300 mg/dose) PO BID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 3: 5 mg/kg/dose (max 300 mg/dose) PO TID. Dose may be further titrated to a maximum dose of 50 mg/day (and generally no more than 1800 mg/day)</td>
<td></td>
</tr>
<tr>
<td>Pregabalin</td>
<td>75 mg BID</td>
<td>Initial adult dose; can titrate up to 300 BID max</td>
</tr>
<tr>
<td>Clonidine</td>
<td>Oral: Immediate release: Initial: 2 mcg/kg/dose every 4 to 6 hours; increase incrementally over several days; range: 2 to 4 mcg/kg/dose every 4 to 6 hours Topical: Transdermal patch: May be switched to the transdermal delivery system after oral therapy is titrated to an optimal and stable dose; a transdermal dose is approximately equivalent to ½ to 1 x the total oral daily dose</td>
<td>Limited data available for pain in children and adolescents. Helps with opioid withdrawal, helps with sleep. Can lower BP. Good for dysautonomia pain.</td>
</tr>
<tr>
<td>Topiramate</td>
<td>-6-12 years (weight greater than or equal to 20 kg): 15 mg PO daily for 7 days, then 15 mg PO BID. =&gt;12 years: 25 mg PO at bedtime for 7 days, then 25 mg PO BID and titrate up to 50 mg PO BID -Maximum daily dose 200mg</td>
<td>May cause acidosis, drowsiness, dizziness, and nausea. Dose adjust for renal impairment and hepatic dysfunction.</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>-0.1 mg/kg PO at bedtime. -titrate as tolerated over 3 weeks to 0.5-2 mg/kg at bedtime. -Maximum: 25mg/dose</td>
<td>Consider for continuous and shooting neuropathic pain. Caution use in patients with arrhythmias. May cause sedation, arrhythmias, dry mouth, orthostasis, and urinary retention. Caution use in patients with seizures; avoid MAOIs, other SSRIs or SNRIs due to potential for serotonin syndrome.</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>Approved for anxiety in children &gt; 7 years. Start with 30 mg capsule at bedtime and can titrate up to 60 mg qHS.</td>
<td>Antidepressants can increase suicidal thinking in pediatric patients with major depressive disorder. Duloxetine may</td>
</tr>
</tbody>
</table>
increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Taper slowly.

Table 5

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Inflammation, Nerve compression</td>
<td>-1 mg/kg/day IV or PO in divided doses every 6 hours. Maximum: 16 mg/day Use lowest effective dose</td>
<td>May cause impaired healing, infection, thrush, hyperglycemia, weight gain, myopathy, stomach upset, psychosis, emotional instability.</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Muscle spasms</td>
<td>Oral: Children: 0.12 to 0.8 mg/kg/day in divided doses every 6 to 8 hours</td>
<td></td>
</tr>
<tr>
<td>Tizanidine</td>
<td>Muscle spasms</td>
<td>Children 2 to &lt;10 years: Oral: 1 mg at bedtime, titrate as needed. Children ≥10 years and Adolescents: Oral: 2 mg at bedtime, titrate as needed.</td>
<td>Oral: Titrate initial dose upward to reported effective range of: 0.3 to 0.5 mg/kg/day in 3 to 4 divided doses; maximum daily dose: 24 mg/day.</td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td>Muscle spasms</td>
<td>Greater than or equal to 15 years old: 5 mg PO  three times daily. Maximum 30 mg/day.</td>
<td></td>
</tr>
<tr>
<td>Dicyclomine</td>
<td>Abdominal cramping</td>
<td>Infants ≥6 months and Children &lt;2 years: Oral: 5 to 10 mg 3 to 4 times daily administered 15 minutes before feeding. Children ≥2 years Oral: 10 mg 3 to 4 times daily. Adolescents: Oral: 10 to 20 mg 3 to 4 times daily. If efficacy not achieved in 2 weeks, therapy should be discontinued.</td>
<td></td>
</tr>
</tbody>
</table>
5% lidocaine patch | Nociceptive or neuropathic pain | 1-3 patches applied daily (depending on size) up to 12 hours per day. | Can be cut to fit

OTC creams | Nociceptive or neuropathic pain | Apply topically to localized areas of neuropathic pain BID-TID

Prescription creams: Diclofenac cream; compounded neuropathic agents | Nociceptive or neuropathic pain | Apply topically to localized areas of neuropathic pain BID-TID

Ice, heat | Nociceptive or neuropathic pain |

Though beyond the scope of this text, pain management can also include palliative radiation and surgical approaches such as dorsal rhizotomy. Consultation with pediatric neurologists, neurosurgeons, pain specialists, and hospice and palliative medicine specialists is prudent in patients with refractory pain. In the rare case where pain control cannot be achieved, the goals-of-care may be consistent with palliative sedation which necessitates consultation with palliative care specialists.78,79,80,81

**Altered Mood**

As brain tumors progress, they often (in 60% of children) cause mood changes. Adolescents, in particular, demonstrate accelerated transitions, notably an "illness transition" in which one identifies with the illness being part of their being, and a "developmental transition" in which development behaviors change in response to the disease.82 However, their growth comes with feelings of sadness, difficulty speaking with their parents, and fear of being alone; and unlike pain which is addressed more than 80% of the time, these emotional symptoms are far less frequently addressed (around 45% of the time).83

Depressed mood should be treated based on severity at presentation. For all patients with mood changes and unbalanced stressors and coping methods, integrative approaches and non-pharmacological options include cognitive behavioral therapy, family therapy, and decreasing stressors where possible. Music, along with other forms of art, are increasingly used to help patients and family members express their emotions.84,85,86 For patients presenting with mild depressive or anxiety symptoms, observation and support are appropriate. For moderate symptom burden, cognitive behavior therapy in addition to medications such as SSRIs, SNRIs, and tricyclic antidepressants should be initiated and selected primarily based on the secondary beneficial effects (i.e. SNRIs for neuropathic pain component, SSRIs for weight gain et cetera). For severe mood symptoms, medications and supportive therapies should be initiated together, psychology and / or psychiatry consultation should be obtained, and disposition should be considered (i.e. admission to facility for safety if suicidal).
Children and adolescents laden with symptoms and weight of disease, may express their burden through requests for hastening of death. AAP guidelines do not support physician-assisted-death; the request should be met with normalization, compassionate care, and aggressive focus on relieving burdens and increasing quality of life. Psychological consultation is important. It is important to remember and communicate that foregoing interventions and thus allowing a disease to progress along its natural course to death is ethically sound, is not suicide, and is not physician-assisted death. Elucidating the patient’s voice about their hopes and fears is powerful; Voicing My Choices and Five Wishes are two studied, standardized tools.

**Agitation, and Altered Mental Status**

Many patients with brain tumors demonstrate agitation, or delirium. Agitation can be caused by direct tumor effects, medical complications (e.g. uremia), and medications (e.g. opioid). Benzodiazepines (midazolam, lorazepam, diazepam, clonazepam) at the lowest possible dose are the primary treatment followed by neuroleptics (haloperidol, thioridazine, chlorpromazine, risperidone), and alpha-agonists (clonidine).

Altered mental status is the most common symptom as children with tumors of the brain approach death (75% of children within the last week of life; 85% overall). This usually manifests as a slow decrease in consciousness over days to weeks. While treatment options are few at this stage of disease, it is important that clinicians provide anticipatory guidance to family and other providers.

**Care of the Family, Caregiver, Siblings**

Palliative care teams maintain the goal of caring not only for the patient, but also for the entire family as they grieve and bereave. The complicated emotion and process of grief and bereavement, respectively, begin at the time of diagnosis and accelerate as attention is turned from cure of disease to palliation of symptoms. Finding meaning and realistic hoped-for goals can soothe patients and families in this phase of care.

While oncology, palliative care, and other interdisciplinary teams have matured areas of disease and symptom management, families report significant deficiencies in psychological care near the end of life. Many family members report unaddressed psychospiritual distress and significant caregiver burdens. Consultation with physical therapy, occupational therapists, child life specialists, art therapists, chaplains, and hospice can provide additional supportive resources. Siblings deserve particular attention and developmentally appropriate interventions such as cognitive behavioral therapy, art and play therapies, and close bereavement follow-up.

Similarly, regardless of the prognosis or the choices in care parents select, disease-specific or pediatric oncological support communities can provide community, validation, and education to the entire family unit; providers should try to connect families to such a group whenever possible.
Summary

Pediatric patients suffering from CNS tumors face difficult clinical decisions and carry significant symptom burden. Given the high risk of mortality, communication of prognosis and goal-setting can be challenging. Supporting caregiver decision making requires honest, empathic communication and attention to the family values and emotions. Ongoing symptom assessment and management is a must to optimize quality of life and reduce suffering. Providers caring for these children should have a basic knowledge of palliative communication skills and pain and symptom management with access to specialist palliative care providers as needed.
Author contributions: Each author contributed substantially to the writing and revisions: Writing – original draft preparation PHB; Writing – Review and Editing KM.

Conflicts of interest: The authors declare no conflict of interest.

References

24 Elisa G. Miller, Chris Feudtner. "Health reform law allows children in hospice to be treated for their disease" AAP News Aug 2013, 34 (8) 14; DOI: 10.1542/aapnews.2013348-14
25 Levine DR; Johnson LM; Mandrell BN; Yang J; West NK; Hinds PS; Baker JN. "Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer". Cancer. 121(9):1508-12, 2015 May 01.
28 Veldhuijzen van Zanten SE; van Meerwijk CL; Jansen MH; Twisk JW; Anderson AK; Coombes L; Breen M; Hargrave OJ; Hemsley J; Craig F; Cruz O; Kaspers GJ; van Vuurden DG; Hargrave DR; SIOPE DIPIG Network. "Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey". Neuro-Oncology. 18(4):582-8, 2016 Apr.
32 Mityanand Ramnarine; David Vearrier. “Anticholinergic Toxicity” Updated: Oct 26, 2017


65 Kelly Komatz, MD, MPH; Brian Carter, MD. “Pain and Symptom Management in Pediatric Palliative Care.” Pediatrics in Review Vol. 36 No. 12 DECEMBER 2015, pp. 527-534


93 Lori Wiener, Elizabeth Ballard, Tara Brennan, Haven Battles, Pedro Martinez, and Maryland Pao. “How I Wish to be Remembered: The Use of an Advance Care Planning Document in Adolescence and Young Adult Populations.” Journal of Palliative Medicine Vol. 11, No. 10
102 Heese O; Vogeler E; Martens T; Schnell O; Tonn JC; Simon M; Schramm J; Krex D; Schackert G; Reithmeier T; Nikkhah G; Sabel M; Steiger HJ; Schlegel U; Loffler M; Weller M; Westphal M; German Glioma Network. "End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey". Neuro-Oncology. 15(9):1251-6, 2013 Sep.